医学
浆液性癌
子宫内膜癌
浆液性液体
肿瘤科
癌
乳腺癌
靶向治疗
内科学
子宫癌
癌症
免疫组织化学
生物标志物
临床试验
妇科
卵巢癌
生物
生物化学
作者
Janira M Navarro Sanchez,Brian S. Finkelman,Bradley M. Turner,Hani Katerji,Xi Wang,Sharlin Varghese,Tiannan Wang,Yan Peng,David G. Hicks,Huina Zhang
摘要
Uterine cancer has the highest incidence and the second-highest mortality rate among gynecologic malignancies in the United States. Although uterine serous carcinoma (USC) represents less than 10% of endometrial carcinomas, it accounts for a disproportionate 50% of tumor relapses and 40% of endometrial cancer deaths. Over the past decade, clinical trials have focused on finding better treatments for this aggressive subtype of endometrial cancer, especially HER2-targeted therapy.We conducted a literature search in PubMed to expand the understanding of HER2 in USC.HER2 has been established as an important biomarker with prognostic and therapeutic implications in USC. Intratumoral heterogeneity and lateral/basolateral membranous staining of HER2 as well as high discordance between HER2 immunohistochemistry and in situ hybridization are more common in USC than in breast carcinoma. Therefore, a universal HER2 testing and scoring system more suitable to endometrial cancer is needed and currently under investigation.This review discusses the clinical perspective of HER2 overexpression/gene amplification in USC, the distinct HER2 staining pattern and the evaluation of HER2 in USC, the resistance mechanisms of HER2-targeted therapy in HER2-positive cancers, and likely areas of future investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI